I reread the agreement parts that DJ catalogued in

I reread the agreement parts that DJ catalogued in the linked post, and it gives Pasaca distribution rights for quantum dots but gives QMC final say on constructing deals for itself from those introductions. If you read Pasaca's website case studies, they expect exponential growth from their portfolio companies. Innova, for example, is on its way Blitzscaling up to 50 million tests per day production. Therefore, QMC HealthID has exponential growth alongside Innova's.

The quote from CEO Squires that I posted a little later indicates he expects exponential growth from the Pasaca's introductions.

Innova owns a huge test manufacturer in China, Xiagen Biotime Biotechnology. Before california, most tests came from there. Their tests use colloidal gold. They have over 35 tests already approved in Europe and other areas. All could improve performance by switching to quantum dots in their tests. All products need anticounterfeiting and QMC HealthID adapted to the specific test. In this decade, blockchain will be ubiquitous attached to products end-to-end supply chains. https://www.medicalexpo.com/soc/xiamen-biotim...28465.html

Most importantly, all China biotech and test manufacturers become potential clients for QMC, with Pasaca vetting the China companies first. China is a huge market.

If one company's Covid test gets huge performance improvement from using Quantum Dots, all most use QD to stay competitive. The market is so big that it is better for the company with the QD IP to license/royalty than to risk overexpansion.

Does expansion into China make the Pasaca deal worthwhile? You betcha.